Frank Torti

CIK: 0001647805

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (18.8%)

Position reduction

Option Exercises (M)3 (18.8%)

Derivative conversions

Awards (A)5 (31.3%)

Compensation grants

Other (G, F, J, C, D, …)5 (31.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ROIV

Roivant Sciences Ltd.

Officer

IMVT

Immunovant, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (16 total)

ROIV
Roivant Sciences Ltd.
Sep 30, 2026
Tax Payment(F)
Direct
40.3K shares at avg. $36.57$1.5M
ROIV
Roivant Sciences Ltd.
Jun 30, 2026
Tax Payment(F)
Direct
40.3K shares at avg. $35.39$1.4M
IMVT
Immunovant, Inc.
Apr 7, 2026
Award(A)
Direct
174.2K shares-
ROIV
Roivant Sciences Ltd.
Mar 31, 2026
Tax Payment(F)
Direct
160K shares at avg. $27.70$4.4M
ROIV
Roivant Sciences Ltd.
Feb 23, 2026
Sale(S)
Direct
587.4K shares at avg. $27.51$16.2M
ROIV
Roivant Sciences Ltd.
Feb 23, 2026
Exercise(M)
Direct
587.4K shares at avg. $3.85$2.3M
ROIV
Roivant Sciences Ltd.
Feb 20, 2026
Exercise(M)
Direct
1M shares at avg. $3.85$3.9M
ROIV
Roivant Sciences Ltd.
Feb 20, 2026
Sale(S)
Direct
1M shares at avg. $27.15$27.5M
ROIV
Roivant Sciences Ltd.
Feb 19, 2026
Exercise(M)
Direct
1.4M shares at avg. $3.85$5.4M
ROIV
Roivant Sciences Ltd.
Feb 19, 2026
Sale(S)
Direct
1.4M shares at avg. $27.42$38.4M
ROIV
Roivant Sciences Ltd.
Dec 24, 2025
Other(J)
Direct
64.9K shares at avg. $22.47$1.5M
ROIV
Roivant Sciences Ltd.
Dec 24, 2025
Gift(G)
Direct
110.5K shares-
ROIV
Roivant Sciences Ltd.
Dec 23, 2025
Award(A)
Direct
175.4K shares at avg. $22.45$3.9M
ROIV
Roivant Sciences Ltd.
Jul 30, 2025
Award(A)
Direct
11.9M shares-
ROIV
Roivant Sciences Ltd.
Jul 30, 2025
Award(A)
Direct
1.8M shares-
IMVT
Immunovant, Inc.
Apr 1, 2025
Award(A)
Direct
199.4K shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	ROIV Roivant Sciences Ltd.	Tax Payment(F)	40,309	$36.57	$1,474,100	Direct
Jun 30, 2026	ROIV Roivant Sciences Ltd.	Tax Payment(F)	40,310	$35.39	$1,426,571	Direct
Apr 7, 2026	IMVT Immunovant, Inc.	Award(A)	174,189	-	$0	Direct
Mar 31, 2026	ROIV Roivant Sciences Ltd.	Tax Payment(F)	160,035	$27.70	$4,432,970	Direct
Feb 23, 2026	ROIV Roivant Sciences Ltd.	Sale(S)	587,390	$27.51	$16,159,099	Direct
Feb 23, 2026	ROIV Roivant Sciences Ltd.	Exercise(M)	587,390	$3.85	$2,261,452	Direct
Feb 20, 2026	ROIV Roivant Sciences Ltd.	Exercise(M)	1,012,610	$3.85	$3,898,549	Direct
Feb 20, 2026	ROIV Roivant Sciences Ltd.	Sale(S)	1,012,610	$27.15	$27,492,362	Direct
Feb 19, 2026	ROIV Roivant Sciences Ltd.	Exercise(M)	1,400,000	$3.85	$5,390,000	Direct
Feb 19, 2026	ROIV Roivant Sciences Ltd.	Sale(S)	1,400,000	$27.42	$38,388,000	Direct
Dec 24, 2025	ROIV Roivant Sciences Ltd.	Other(J)	64,891	$22.47	$1,458,101	Direct
Dec 24, 2025	ROIV Roivant Sciences Ltd.	Gift(G)	110,489	-	-	Direct
Dec 23, 2025	ROIV Roivant Sciences Ltd.	Award(A)	175,380	$22.45	$3,937,281	Direct
Jul 30, 2025	ROIV Roivant Sciences Ltd.	Award(A)	11,900,000	-	-	Direct
Jul 30, 2025	ROIV Roivant Sciences Ltd.	Award(A)	1,836,547	-	-	Direct
Apr 1, 2025	IMVT Immunovant, Inc.	Award(A)	199,365	-	-	Direct

1-16 of 16 transactions

About Torti Frank

Torti Frank (SEC CIK 0001647805) files insider reports with the SEC as President and Vant Chair of Roivant Sciences Ltd. (ROIV) and Director of Immunovant, Inc. (IMVT).

Signal8 holds 9 ownership filings by Torti Frank (1 Form 3, 8 Form 4), filed between Apr 3, 2025 and Oct 2, 2026. Those filings report 16 transactions, from Apr 1, 2025 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Torti Frank's filings is in LONDON.

Recent filings by Torti Frank

Sep 30, 2026: Tax withholding of ROIV shares (Form 4, code F).
Jun 30, 2026: Tax withholding of ROIV shares (Form 4, code F).
Apr 7, 2026: Grant or award of IMVT shares (Form 4, code A).
Mar 31, 2026: Tax withholding of ROIV shares (Form 4, code F).
Feb 23, 2026: Open-market sale of ROIV shares (Form 4, code S).

Other insiders filing for Roivant Sciences Ltd. (ROIV)

Venker Eric, President & Immunovant CEO
Oren Ilan, Director
Epperly Melissa B,, Director
MOMTAZEE JAMES C, Director
Sukhatme Mayukh, President & CIO
Gline Matthew, CEO

How to read Form 4 transaction codes